OctreoScan
WikiDoc Resources for OctreoScan |
Articles |
---|
Most recent articles on OctreoScan |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on OctreoScan at Clinical Trials.gov Clinical Trials on OctreoScan at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on OctreoScan
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on OctreoScan Discussion groups on OctreoScan Patient Handouts on OctreoScan Directions to Hospitals Treating OctreoScan Risk calculators and risk factors for OctreoScan
|
Healthcare Provider Resources |
Causes & Risk Factors for OctreoScan |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
OctreoScan is a kit for the preparation of Indium In-111 pentetreotide, a diagnostic radiopharmaceutical.
Indications for OctreoScan imaging
- Tumor evaluation
Patient preparation
- Bowel preparation with laxative and enema
- Discontinue octeotide therapy for 1 week prior the exam
Radiopharmaceutical
- In-111 OctreoScan
Dose and route of administration
- 6 mCi IV
- 4 hours (abdomen, pelvis)
- 24 hours (whole body)
Equipment
- Camera: Large field of view SPECT gamma camera
- Collimator: Medium-energy
- Window: 20% window around 173 and 245 KeV
Procedure
- 4 hours: Planar images of the abdomen and pelvis
- 24 hours: Planar images of the whole body. SPECT of regions of clinical concern.
Images
Normal OctreoScan
References
- Ziessman, Harvey A, O'Malley, Janis P, and Thrall, James M. Nuclear Medicine: The Requisites. 3rd ed. Philadelphia, Pennsylvania: Mosby, 2006. ISBN 0323029469